Vallon Pharmaceuticals Presents Positive Data from Pilot Intranasal Human Abuse Study of Its Investigational Abuse Deterrent Stimulant, ADAIR, at the American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting
Vallon Pharmaceuticals Inc., a specialty pharmaceutical company focused on the development of novel drugs for CNS disorders, today announced the presentation of positive data from a pilot study assessing human abuse liability for its investigational Abuse Deterrent Amphetamine Immediate Release (ADAIR).
Other Articles in this Edition
Will the FDA give the go-ahead to a prescription video game? The wait goes on, as new data come in
How to Address Mental Health In the Workplace
Report guides pediatricians in care of maltreated children, including pharmacotherapy
Scientists reveal ADHD medication’s effect on the brain
Video Game Based Digital Therapy Looks Promising in Pediatric ADHD Trial
ADHD, THE MUSIC BUSINESS, AND ME
Mix of stress and air pollution may lead to cognitive difficulties in children
Detroit Area Specialists Teach Women How to Thrive with ADHD
Scant evidence that pharmaceutical CBD or medicinal cannabis can reduce symptoms of mental disorders